{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:00:01Z","timestamp":1777950001433,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>We report a rare case of 32-year-old female with malignant reninoma complicated by pulmonary metastasis and ATRX mutation (p.G1964*, VAF 23.73%), initially misdiagnosed as renal pelvic carcinoma and treated with radical left nephrectomy and ureterectomy. The patient developed local recurrence and pancreatic head metastasis in January 2025, with stable disease achieved after radiotherapy, EP chemotherapy and toripalimab immunotherapy. Subsequent olaparib targeted therapy led to resolution of renal recurrent tumor, but progressive pancreatic lesion and persistent pulmonary metastasis were observed, suggesting tumor heterogeneity. This case demonstrates the value of NGS in screening actionable molecular targets for rare malignant reninoma; olaparib yields favorable local control for ATRX-mutated malignant reninoma based on synthetic lethality, while the differential response at metastatic sites underscores the need for exploring combination therapies to overcome tumor heterogeneity and drug resistance, providing a clinical reference for precision treatment of this rare disease.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1803771","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:31:52Z","timestamp":1777872712000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Malignant reninoma with pulmonary metastasis and ATRX mutation treated with olaparib: a case report of specialized treatment"],"prefix":"10.3389","volume":"17","author":[{"given":"Guo run","family":"Zi","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-jiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Lin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Run-lin","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-xing","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"B1","article-title":"Urinary and male genital tumours","volume-title":"WHO classification of tumours series","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(67)90256-2","article-title":"Hypertension due to a renin-secreting renal tumour","volume":"43","author":"Robertson","year":"1967","journal-title":"Am J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1440-1827.1968.tb00048.x","article-title":"A hitherto unreported vascular tumor of the kidney: a proposal of \u201cjuxtaglomerular cell tumor","volume":"18","author":"Kihara","year":"1968","journal-title":"Acta Pathol Jpn"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.12659\/msm.913826","article-title":"Minimally invasive surgery-based multidisciplinary clinical management of reninoma: a single-center study","volume":"25","author":"Liu","year":"2019","journal-title":"Med Sci Monit"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad516","article-title":"Approach to the patient: reninoma","volume":"109","author":"Hayes","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01804-0","article-title":"Unravelling a mystery of hypokalemic hypertension- a rare case report of a reninoma","volume":"24","author":"Pathirana","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41118-8","article-title":"Targetable NOTCH1 rearrangements in reninoma","volume":"14","author":"Treger","year":"2023","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.09.005","article-title":"Usefulness of magnetic resonance imaging in the diagnosis of juxtaglomerular cell tumors: a report of 10 cases and review of the literature","volume":"73","author":"Faucon","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/criu\/8149819","article-title":"Surgical curative approach for severe hypertension in select patients with underrecognized rare renal tumors: a case report","volume":"2025","author":"McGreal","year":"2025","journal-title":"Case Rep Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105939","article-title":"Insights from single cell and bulk RNA sequencing: increased NOTCH signaling is correlated with oncogenic transformation of juxtaglomerular cells to juxtaglomerular cell tumors","volume":"165","author":"Gupta","year":"2025","journal-title":"Hum Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/ki.2010.445","article-title":"Reninoma","volume":"79","author":"Chao","year":"2011","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-024-01606-w","article-title":"Clinical features, laboratory findings and treatment of juxtaglomerular cell tumors: a systemic review","volume":"47","author":"Dong","year":"2024","journal-title":"Hypertens Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30068","article-title":"Juxtaglomerular cell tumor with pulmonary metastases: a case report and review of the literature","volume":"70","author":"Sakiyama","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1133832","article-title":"Treatment strategies for clear cell renal cell carcinoma: past, present and future","volume":"13","author":"Yang","year":"2023","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1648756","article-title":"Rare renal tumor: a case report of juxtaglomerular cell tumor and literature review","volume":"15","author":"Zhu","year":"2025","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2025.108537","article-title":"From pathology to therapy: a comprehensive review of ATRX mutation related molecular functions and disorders","volume":"795","author":"Xu","year":"2025","journal-title":"Mutat Res Rev Mutat Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04299-5","article-title":"Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial","author":"Park","year":"2026","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-026-00206-0","article-title":"Cosegregation analysis following an excellent response to olaparib in a pancreatic cancer patient carrier of BRCA2:c.7892\u2009T\u2009>\u2009C variant enables its reclassification from VUS to pathogenic","volume":"4","author":"Strojnik","year":"2026","journal-title":"BJC Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01604","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108761","article-title":"From bench to bedside: synthetic strategies and clinical application of PARP inhibitors","volume":"163","author":"Man","year":"2025","journal-title":"Bioorg Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102971","article-title":"Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma","volume":"59","author":"George","year":"2020","journal-title":"EBioMedicine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001160","article-title":"Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report","volume":"33","author":"Wu","year":"2022","journal-title":"Anticancer Drugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01167-9","article-title":"PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications","volume":"19","author":"Zhu","year":"2020","journal-title":"Mol Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03051-z","article-title":"Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma","volume":"133","author":"Herbert","year":"2025","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/d41573-021-00078-8","article-title":"Enhancing sensitivity to PARP inhibitors","volume":"20","author":"Crunkhorn","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1803771\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:31:53Z","timestamp":1777872713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1803771\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1803771"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1803771","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"article-number":"1803771"}}